Plasma amylin immunoreactivity and insulin resistance in insulin resistant relatives of patients with non-insulin-dependent diabetes mellitus

Hormone and Metabolic Research

Volumn 30, Issue 4, 1998, Pages 206-212

  Nyholm, B ^a   Fineman, M S ^b   Koda, J E ^b   Schmitz, O ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b AMYLIN PHARMACEUTICALS INC   (United States)

Author keywords

Amylin; Immunoassays; Insulin; Insulin resistance; Non insulin dependent diabetes mellitus; Prediabetic state

Indexed keywords

AMYLIN; GLUCOSE; INSULIN;

ADULT; ARTICLE; CLAMP; CLINICAL ARTICLE; CONTROLLED STUDY; FAMILY HISTORY; FAMILY STUDY; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE TRANSPORT; HUMAN; IMMUNOASSAY; IMMUNOREACTIVITY; IMPAIRED GLUCOSE TOLERANCE; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; INSULIN SENSITIVITY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL GLUCOSE TOLERANCE TEST; PRIORITY JOURNAL;

EID: 0031941999     PISSN: 00185043     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-978867     Document Type: Article

References (42)

1. Eriksson J, Franssila-Kallunki A, Ekstrand A, Saloranta C, Widèn E, Schalin C, Groop L. Early metabolic defects in persons at increased risk for non-insulin-dependent diabetes mellitus. N Engl J Med 1989; 321: 337-43
2. Warram JH, Martin BC, Krolewski AS, Soeldner JS, Kahn CR. Slow glucose removal rate and hyperinsulinemia precede the development of type II diabetes in the offspring of diabetic parents. Ann Intern Med 1990; 113: 909-15
3. Vaag A, Henriksen JE, Beck-Nielsen H. Decreased insulin activation of glycogen synthase in skeletal muscles in young nonobese caucasian first-degree relatives of patients with non-insulin-dependent diabetes mellitus. J Clin Invest 1992; 89: 782-8
4. Gulli G, Ferrannini E, Stern M, Haffner S, DeFronzo A. The metabolism profile of NIDDM is fully established in glucose-tolerant offspring of two Mexican-American NIDDM parents. Diabetes 1992; 41: 1575-86
5. Nyholm B, Mengel A, Nielsen S, Skjærbaek C, Møller N, Alberti KGMM, Schmitz O. Insulin resistance in relatives of patients with non-insulin-dependent diabetes mellitus: the role of physical fitness and muscle metabolism. Diabetologia 1996; 39: 813-22
6. Lillioja S, Mott DM, Spraul M, Ferraro R, Foley JE, Ravussin E, Knowler WC, Bennet PH, Bogardus C. Insulin resistance and insulin secretory dysfunction as precursors of non-insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 1988-92
7. Beck-Nielsen H, Groop L. Metabolic and genetic characterization of prediabetic states. J Clin Invest 1994; 94: 1714-21
8. Yki-Järvinen H. Role of insulin resistance in the pathogenesis of NIDDM. Diabetologia 1995, 38: 1378-88
9. DeFronzo RA, Jacot E, Jequier E, Maeder E, Wahren J, Felber JP. The effect of insulin on the disposal of intravenous glucose. Diabetes 1981: 30: 1000-7
10. Castillo MJ, Scheen AJ, Lefèbvre PJ. Amylin/islet amyloid polypeptide: biochemistry, physiology and patho-physiology. Diabete Metab 1995; 21: 3-26
11. Clark A, Badman MK, de Koning EJP. Islet amyloid, islet amyloid polypeptide, islet function and glucose metabolism in diabetes. In: Marshall SM, Home PD, Rizza RA. (editors). The Diabetes Annual vol 9. Elsevier Science B.V. 1995: 33-56
12. Ludvik B, Lell B, Hartter E, Schnack C, Pranger R. Decrease of stimulated amylin release precedes impairment of insulin secretion in type II diabetes. Diabetes 1991; 40: 1615-9
13. Enoki S, Mitsukawa T, Takemura J, Nakazato M, Aburaya J, Toshimori H, Matsukara S. Plasma islet amyloid polypeptide levels in obesity, impaired glucose tolerance and non-insulin-dependent diabetes mellitus. Diabetes Res Clin Pract 1992; 15: 97-102
14. Blackard WG, Clore JN, Kellum JM. Amylin/insulin secretory ratios in morbidly obese man. Inverse relationship with glucose disappearance rate. J Clin Endocrinol Metab 1994; 78: 1257-60
15. Eriksson J, Nakazato M, Miyazato M, Shiomi K, Matsukura S, Groop L. Islet amyloid polypeptide plasma concentrations in individuals at increased risk of developing type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 1992; 35: 291-3
16. Percy A, Trainor DA, Rittenhouse J, Phelps J, Koda JE. Development of sensitive immunoassay to detect amylin and amylin-like peptides in unextracted plasma. Clin Chem 1996; 42: 576-85
17. Rittenhouse J, Chait BT, Bierle JR, Janes SM, Park DR, Phelps JL, Fineman MS, Quin J, Koda JE. Heterogeneity of naturally-occuring human amylin due to glycosylation. Diabetes 1996; 45 (suppl 2): 234 A, 867 (abstract)
18. Fineman MS, Koda JE, Percy A, Wareham NJ, Hales CN. Elevation of high molecular weight amylin-like peptides along with proinsulin and 32,33 split proinsulin in newly diagnoses diabetics. Diabetologia 1994; 37 (suppl 1): A52, 197 (abstract)
19. Wareham NJ, Swinn R, Fineman MS, Koda JE, Taylor K, O'Rahilly S. The concentration of glycosylated amylin species is increased in women with gestational diabetes mellitus. Diabetic Medicine 1996; 13 (suppl 13): s44, P111 (abstract)
20. Nyholm B, Fisker S, Lund S, Møller N, Schmitz O. Increased circulating leptin concentration in insulin resistant first-degree relatives of patients with non-insulin-dependent diabetes mellitus: Relationship to body composition and insulin sensitivity but not to family history of non-insulin-dependent diabetes mellitus. European J Endocrinol 1997; 136: 173-9
21. Gray SD. Effect of obesity on bioelectrical impedance. Am J Clin Nutr 1989; 50: 255-60
22. National Diabetes Data Group. Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. Diabetes 1979; 28: 1039-57
23. Åstrand I. Aerobic work capacity of men and women with special reference to age. Acta Physiol Scand (Suppl) 1960: 169:49-92
24. DeFronzo RA, Tobin JD, Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol 1979; 237: E214-23
25. Finegood DT, Bergman RN, Vranic M. Estimation of endogenous glucose production during hyperinsulinemic-euglycemic glucose clamps: comparison of unlabeled and labeled exogenous glucose infusates. Diabetes 1987; 36: 914-24
26. Andersen L, Dinesen B, Jørgensen PN, Poulsen F, Røder ME. Enzyme immunoassay for intact human insulin in serum or plasma. Clin Chem 1993; 39: 578-82
27. Leighton B, Cooper GJS. Pancreatic amylin and calcitonin generelated peptide causes resistance to insulin in skeletal muscle in vitro. Nature 1988; 355: 632-5
28. Young AA, Gedulin B, Wolfe-Lopez D, Greene HE, Rink T, Cooper GJSI. Amylin and insulin in rat soleus muscle: dose responses for co-secreted noncompetitive antagonists. Am J Phyisol 1992; 263: E274-81
29. Sowa R, Sanke T, Hirayama J, Tabata H, Furuta H, Nishimura S, Nanjo K. Islet amyloid polypeptide amid causes peripheral insulin resistance in dogs. Diabetologia 1990; 33: 118-20
30. Frontoni S, Choi SB, Banduch D, Rossetti L. In vivo insulin resistance induced by amylin primary through inhibition of insulin-stimulated glycogen synthesis in skeletal muscle. Diabetes 1991; 40: 568-73
31. Bretherton-Watt D, Gilby SG, Ghatei MA, Baecham J, Bloom S. Failure to establish islet amyloid polypeptide (amylin) as a circulating beta cell inhibiting hormone in man. Diabetologia 1990; 33: 115-7
32. Bretherton-Watt D, Gilby SG, Ghatei MA, Baecham J, Macrae D, Bloom S. Very high concentrations of islet amyloid polypeptide are necessary to alter the insulin response to intravenous glucose in man. J Clin Endocrinol Metab 1992; 74: 1032-5
33. Wilding JPH, Khandan-Nia N, Bennet WM, Gilbey SG, Beacham J, Ghatei MA, Bloom SR. Lack of acute effect of amylin (islet associated polypeptide) on insulin sensitivity during hyperinsulinemic euglycemic clamp in humans. Diabetologia 1994; 37: 166-9
34. Nyholm B, Møller N, Gravholt CH, Ørskov L, Mengel A, Bryan G, Moyses C, Alberti KGMM, Schmitz O. Acute effects of the human amylin analogue AC 137 on basal and insulin-stimulated euglycemic and hypoglyce;mic fuel metabolism in patients with insulin-dependent-diabetes mellitus. J Clin Endocrinol Metab 1996; 81: 1083-9
35. Butler PC, Chou J, Carter WB, Wang YN, Bu BH, Chang DC, Chang JK, Rizza RAI. Effects of meal ingestion on plasma amylin concentration in NIDDM and nondiabetic humans. Diabetes 1990; 39: 752-6
36. Nakazato M, Asai J, Kangawa K, Matsukura S, Matsuo H. Establishment of radioimmunoassay for human islet amyloid polypeptide and its tissue content and plasma concentration. Biochem Biophys Res Commun 1989; 164: 394-9
37. Shiomi K, Nakazato M, Miyazato M, Kangawa K, Matsuo H, Matsukura S. Establishment of hypersensitive radioimmunoassay for islet amyloid polypeptide using antiserum specific for its N-terminal region. Biochem Biophys Res Commun 1992; 186: 1065-73
38. van Hulst KL, Hackeng WHL, Höppener JWM, van Jaarsveld BC, Nieuwenhuis MG, Blankenstein MA, Lips CJM. An improved method for the determination of islet amyloid polypeptide levels in plasma. Ann Clin Biochem 1994; 31: 165-70
39. Williams DEM, Wareham NJ, Fineman MS, Koda JE, Anderson SG, Day NE, Hales CN. Fasting plasma total amylin concentrations predicts detoration in glucose tolerance over 4.5 years. Diabetologia 1997; 40 (suppl 1): A 202, 791 (abstract)
40. Hartter E, Svoboda T, Ludvik B, Schuller M, Lell B, Kuenburg E, Brunnbauer M, Woloszczuk W, Pranger R. Basal and stimulated plasma levels of pancreatic amylin indicate its co-secretion with insulin in humans. Diabetologia 1991; 34: 52-4
41. Mitsukawa T, Takemura J, Asai J, Nakazato M, Kangawa K, Matsuo H, Matsukura S. Islet amyloid polypeptide response to glucose, insulin, and somatostatin analogue administration. Diabetes 1990; 39: 639-42
42. Gedulin B, Cooper GJS, Young A. Amylin secretion from the perfused pancreas: Dissociation from insulin and abnormal elevation in insulin-resistant diabetic rats. Biochem Biophys Res Commun 1991; 180: 782-9